The US Food and Drug Administration (FDA) has accepted a resubmission of the supplemental Biologics License Application for ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Regenxbio shares surged 20% after disclosing new, positive efficacy and safety data of its Duchenne muscular dystrophy treatment. Shares were recently trading around $11.55. The stock is down 46% on ...

The primary endpoint of achieving microdystrophin expression of at least 10% was met by all participants in the current trial phase, suggesting a high probability of positive outcomes for the pivotal ...

Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...

This dual-track strategy enables Dyadic to capitalize on near-term milestones, generating license revenue and achieving ...

"We now look forward to submitting a Biologics License Application to the Food and Drug Administration by end of this year, followed by a Marketing Authorization Application to the European Medicines ...

HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical moleculesHCW ...

Aclaris Therapeutics (ACRS) shares surge 13% after exclusive global license deal for potential best-in-class biologics assets to bolster its pipeline.

HCW Biologics shares skyrocketed as the company entered a licensing agreement with China's WY Biotech for an immunotherapeutic product candidate.

The deal is focused on a preclinical molecule that could potentially be used to treat age-related illnesses, such as cancer.

U.S.-based HCW Biologics' (NASDAQ:HCWB) shares rallied in Monday's premarket trade, driven by a license, research and ...